VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

被引：32

作者：

Lu, S. ^{[1
]}

Wu, L. ^{[2
]}

Jian, H. ^{[1
]}

Cheng, Y. ^{[3
]}

Wang, Q. ^{[4
]}

Fang, J. ^{[5
]}

Wang, Z. ^{[5
]}

Hu, Y. ^{[6
]}

Sun, M. ^{[7
]}

Han, L. ^{[8
]}

Miao, L. ^{[9
]}

Ding, C. ^{[10
]}

Cui, J. ^{[11
]}

Li, B. ^{[12
]}

Li, X. ^{[13
]}

Wang, K. ^{[14
]}

Cang, S. ^{[15
]}

Pan, Y. ^{[16
]}

Ye, F. ^{[17
]}

Liu, A. ^{[18
]}

机构：

[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China

[2] Hunan Canc Hosp, Dept Thorac Med Oncol, Changsha, Peoples R China

[3] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China

[4] Henan Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China

[5] Peking Univ, Dept Thorac Med Oncol, Canc Hosp, Beijing, Peoples R China

[6] Hubei Canc Hosp, Dept Thorac Med Oncol, Wuhan, Peoples R China

[7] Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China

[8] Xuzhou Cent Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China

[9] Nanjing Drum Tower Hosp, Dept Resp Med, Nanjing, Peoples R China

[10] Hebei Med Univ, Dept Resp Med, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[11] Jilin Univ, Dept Oncol, Bethune Hosp 1, Changchun, Peoples R China

[12] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China

[13] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China

[14] Sichuan Univ, Dept Resp Med, West China Hosp, Chengdu, Peoples R China

[15] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Peoples R China

[16] Anhui Prov Hosp, Dept Oncol, Hefei, Peoples R China

[17] Hosp Xiamen Univ, Dept Oncol, Affiliated 1, Xiamen, Peoples R China

[18] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 01期

关键词：

D O I：

10.1016/j.annonc.2021.10.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：112 / 113

页数：2